Key result
Renal denervation for hypertension faces challenges regarding efficacy and patient selection, necessitating future randomized sham-controlled trials to identify responders and optimize techniques.
Why the study?
Does renal denervation reduce blood pressure in patients with resistant hypertension compared to sham control?
Population
Patients with sympathetic hyperactivity associated disease states, such as resistant hypertension
Comparison
Renal denervation (RDN) vs Sham control
Design
Editorial
Authors
Loading...
Warrants caution with RDN for hypertension; leaves open refined techniques in selected patients.
Does renal denervation reduce blood pressure in patients with resistant hypertension compared to sham control?
The editorial emphasizes the critical need for randomized, sham-controlled phase 3 trials to accurately assess the efficacy of renal denervation for hypertension, given the neutral results of prior rigorous trials and the methodological flaws of observational studies.
Michiel Voskuil (2016) conducted an editorial in Hypertension. Renal denervation was evaluated. Renal denervation for hypertension faces challenges regarding efficacy and patient selection, necessitating future randomized sham-controlled trials to identify responders and optimize techniques.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: